Cargando…

Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients

BACKGROUND: Endocan is a soluble dermatan sulfate proteoglycan (50 kDa) secreted by endothelial cells and expressed by dermal, coronary, pulmonary and adipose tissue microvasculature. It plays an important role in the pathogenesis of vascular disorders, inflammatory state, endothelium dysfunction an...

Descripción completa

Detalles Bibliográficos
Autores principales: Morace, Carmela, Curatola, Selenia Lorenza, Mandraffino, Giuseppe, Scuruchi, Michele, Serrano’, Angela Elvira, Tropeano, Angelo, Lombardo, Fortunato, Salzano, Giuseppina, Squadrito, Giovanni, Versace, Antonio Giovanni, Valenzise, Mariella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468868/
https://www.ncbi.nlm.nih.gov/pubmed/37653524
http://dx.doi.org/10.1186/s13052-023-01510-y
_version_ 1785099318376529920
author Morace, Carmela
Curatola, Selenia Lorenza
Mandraffino, Giuseppe
Scuruchi, Michele
Serrano’, Angela Elvira
Tropeano, Angelo
Lombardo, Fortunato
Salzano, Giuseppina
Squadrito, Giovanni
Versace, Antonio Giovanni
Valenzise, Mariella
author_facet Morace, Carmela
Curatola, Selenia Lorenza
Mandraffino, Giuseppe
Scuruchi, Michele
Serrano’, Angela Elvira
Tropeano, Angelo
Lombardo, Fortunato
Salzano, Giuseppina
Squadrito, Giovanni
Versace, Antonio Giovanni
Valenzise, Mariella
author_sort Morace, Carmela
collection PubMed
description BACKGROUND: Endocan is a soluble dermatan sulfate proteoglycan (50 kDa) secreted by endothelial cells and expressed by dermal, coronary, pulmonary and adipose tissue microvasculature. It plays an important role in the pathogenesis of vascular disorders, inflammatory state, endothelium dysfunction and neoangiogenesis. Aims of the study were to compare fasting serum endocan levels between children with obesity and healthy controls and to investigate the relationships between endocan, body mass index (BMI) and other indices of cardiometabolic risk. METHODS: This single-center, observational, retrospective study included 19 pediatric patients with obesity aged 11.94 ± 0.52 years and 19 lean matched controls. Each patient underwent clinical and auxological examination and laboratory investigations including routine organs function tests and lipid profile. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Fasting endocan serum levels were measured using an enzyme-linked immunosorbent assay (ELISA). RESULTS: Compared to healthy subjects, serum endocan levels were found to be significantly upraised in children with obesity. Endocan resulted significantly correlated with insulin levels (rho 0.47; p = 0.04); in addition, an association with HOMA-IR values with a trend toward the statistical significance (rho 0.43; p = 0.07) was found. No significant correlation with fasting blood glucose values and lipid serum levels was demonstrated. Although not statistically significant, a correlation between endocan and the presence and grading of liver steatosis on ultrasound (rho 0.51; p = 0.08 and rho 0.51; p = 0.08, respectively) was found. CONCLUSIONS: These findings confirm the association between endothelial damage and insulin resistance in children with obesity. Endocan could be used as a biomarker of early endothelial dysfunction in children with obesity and could be a valid predictor of future cardiovascular risk in adulthood.
format Online
Article
Text
id pubmed-10468868
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104688682023-09-01 Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients Morace, Carmela Curatola, Selenia Lorenza Mandraffino, Giuseppe Scuruchi, Michele Serrano’, Angela Elvira Tropeano, Angelo Lombardo, Fortunato Salzano, Giuseppina Squadrito, Giovanni Versace, Antonio Giovanni Valenzise, Mariella Ital J Pediatr Research BACKGROUND: Endocan is a soluble dermatan sulfate proteoglycan (50 kDa) secreted by endothelial cells and expressed by dermal, coronary, pulmonary and adipose tissue microvasculature. It plays an important role in the pathogenesis of vascular disorders, inflammatory state, endothelium dysfunction and neoangiogenesis. Aims of the study were to compare fasting serum endocan levels between children with obesity and healthy controls and to investigate the relationships between endocan, body mass index (BMI) and other indices of cardiometabolic risk. METHODS: This single-center, observational, retrospective study included 19 pediatric patients with obesity aged 11.94 ± 0.52 years and 19 lean matched controls. Each patient underwent clinical and auxological examination and laboratory investigations including routine organs function tests and lipid profile. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Fasting endocan serum levels were measured using an enzyme-linked immunosorbent assay (ELISA). RESULTS: Compared to healthy subjects, serum endocan levels were found to be significantly upraised in children with obesity. Endocan resulted significantly correlated with insulin levels (rho 0.47; p = 0.04); in addition, an association with HOMA-IR values with a trend toward the statistical significance (rho 0.43; p = 0.07) was found. No significant correlation with fasting blood glucose values and lipid serum levels was demonstrated. Although not statistically significant, a correlation between endocan and the presence and grading of liver steatosis on ultrasound (rho 0.51; p = 0.08 and rho 0.51; p = 0.08, respectively) was found. CONCLUSIONS: These findings confirm the association between endothelial damage and insulin resistance in children with obesity. Endocan could be used as a biomarker of early endothelial dysfunction in children with obesity and could be a valid predictor of future cardiovascular risk in adulthood. BioMed Central 2023-08-31 /pmc/articles/PMC10468868/ /pubmed/37653524 http://dx.doi.org/10.1186/s13052-023-01510-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Morace, Carmela
Curatola, Selenia Lorenza
Mandraffino, Giuseppe
Scuruchi, Michele
Serrano’, Angela Elvira
Tropeano, Angelo
Lombardo, Fortunato
Salzano, Giuseppina
Squadrito, Giovanni
Versace, Antonio Giovanni
Valenzise, Mariella
Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients
title Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients
title_full Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients
title_fullStr Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients
title_full_unstemmed Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients
title_short Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients
title_sort serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468868/
https://www.ncbi.nlm.nih.gov/pubmed/37653524
http://dx.doi.org/10.1186/s13052-023-01510-y
work_keys_str_mv AT moracecarmela serumendocanasapredictivebiomarkerofcardiovascularriskinobesepediatricpatients
AT curatolaselenialorenza serumendocanasapredictivebiomarkerofcardiovascularriskinobesepediatricpatients
AT mandraffinogiuseppe serumendocanasapredictivebiomarkerofcardiovascularriskinobesepediatricpatients
AT scuruchimichele serumendocanasapredictivebiomarkerofcardiovascularriskinobesepediatricpatients
AT serranoangelaelvira serumendocanasapredictivebiomarkerofcardiovascularriskinobesepediatricpatients
AT tropeanoangelo serumendocanasapredictivebiomarkerofcardiovascularriskinobesepediatricpatients
AT lombardofortunato serumendocanasapredictivebiomarkerofcardiovascularriskinobesepediatricpatients
AT salzanogiuseppina serumendocanasapredictivebiomarkerofcardiovascularriskinobesepediatricpatients
AT squadritogiovanni serumendocanasapredictivebiomarkerofcardiovascularriskinobesepediatricpatients
AT versaceantoniogiovanni serumendocanasapredictivebiomarkerofcardiovascularriskinobesepediatricpatients
AT valenzisemariella serumendocanasapredictivebiomarkerofcardiovascularriskinobesepediatricpatients